Trial Profile
A Single-Center, Non-Randomized, Open-Label, One-Sequence, Two-Period Within-Subject Study to Investigate the Effect of Rifampicin on the Pharmacokinetics of Multiple Doses of Balovaptin In Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Nov 2019
Price :
$35
*
At a glance
- Drugs Balovaptan (Primary) ; Rifampicin
- Indications Autistic disorder
- Focus Pharmacokinetics
- Sponsors Roche
- 17 Jan 2019 Status changed from active, no longer recruiting to completed.
- 13 Nov 2018 Planned End Date changed from 22 Nov 2018 to 15 Nov 2018.
- 23 Oct 2018 Planned primary completion date changed from 2 Sep 2018 to 26 Oct 2018.